Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 5Cisplatin 5Platinum 4Pemetrexed 41,2-diaminocyclohexaneplatinum II citrate 4Nivolumab 3Cyclophosphamide 3fludarabine 2atezolizumab 2Ipilimumab 2Carboplatin 2tremelimumab 1sargramostim 1methoxyamine 1lenvatinib 1cediranib 1anetumab ravtansine 1UV1 vaccine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Interleukin-2 1Imprint II 1Immunotherapy, Adoptive 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Bevacizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × methoxyamine × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡